Bisheng Biotechnology

Bisheng Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of mRNA-based vaccines and therapeutics. Headquartered in Suzhou, China, the company utilizes its proprietary mRNA design and lipid nanoparticle (LNP) delivery platforms to create treatments for infectious diseases and various cancers. Their pipeline includes a lead mRNA vaccine candidate for COVID-19, which has entered clinical trials, and several preclinical programs in oncology. Bisheng is committed to advancing the field of nucleic acid medicine through integrated R&D and manufacturing capabilities. The company is backed by prominent venture capital firms and aims to provide rapid-response solutions to global health threats.